All of WSIPP's research is published on our website. The Publications page includes every report we've released—from our founding in 1983 to the present. Each report entry includes the title, publication date, abstract, any available supplemental materials, and a downloadable PDF.
WSIPP reports are not updated after publication, and any report older than two years is designated with an “Archived” label.
To explore our benefit-cost and meta-analytic findings, please visit the Benefit-Cost section of the website.
Use the search fields below to find specific publications that match certain criteria. If you want to find other information on our website that is not publications, you can use the search field in the navigation bar at the top, or click here to search the entire website.
Found 1 results
In November 2012, Washington State voters passed Initiative 502 (I-502), which legalized limited possession, private use, and commercial sales of cannabis for adults. In this report, we examined if greater access to licensed non-medical cannabis (NMC) retailers relates to disordered substance use diagnoses among Medicaid beneficiaries in Washington State. We found that a lower average travel time to an NMC retailer predicts a small increase in the probability that a claim includes a diagnosis of cannabis use disorder (CUD), alcohol use disorder (AUD), or opioid use disorder (OUD) among Medicaid beneficiaries ages 21 and older and beneficiaries ages 12-17. We also found that in neighborhoods with multiple retailers located in proximity (within 5 or 10 minutes), an increase in the number of retailers predicts a higher likelihood of CUD.